Therapeutic Asset Ratings

3,229 results matching 1 filter

91,564 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Atezolizumab Liver Cancer	Niek Wijnen	P4	B (62)
Atogepant Tinnitus	Stanford University	P4	B (62)
Atorvastatin Dementia	Duke University	P4	B (62)
Azathioprine Hepatocellular Carcinoma	Baylor Research Institute	P4	B (62)
Bendamustine Hodgkins Lymphoma	University Hospital, Bordeaux	P4	B (62)
Biktarvy HIV Infectious Disease	East Carolina University	P4	B (62)
Binimetinib Metastatic Melanoma	SRH Wald-Klinikum Gera GmbH	P4	B (62)
Bms-986374 Relapsing-Remitting Multiple Sclerosis	Bristol-Myers Squibb	P4	B (62)
Bortezomib Acute Lymphoblastic Leukemia	Instituto do Cancer do Estado de São Paulo	P4	B (62)
Buspirone Traumatic Brain Injury	Massachusetts General Hospital	P4	B (62)
Buspirone Depressive Disorder	Massachusetts General Hospital	P4	B (62)
Canagliflozin Polycystic Ovary Syndrome	Ping Li,MD	P4	B (62)
Candesartan Tinnitus	Stanford University	P4	B (62)
Capecitabine Head And Neck Neoplasm	Rutgers, The State University of New Jersey	P4	B (62)
Carbidopa Stroke Disorder	University Hospital, Basel, Switzerland	P4	B (62)
Carvedilol Portal Vein Thrombosis	Asian Institute Of Medical Sciences	P4	B (62)
Cediranib Colorectal Cancer	University Health Network, Toronto	P4	B (62)
Cefadroxil Anhydrous Autoimmune Disease	Mayo Clinic	P4	B (62)
Cefadroxil Anhydrous Diabetes Mellitus	Mayo Clinic	P4	B (62)
Cefadroxil Anhydrous Obesity Disorder	Mayo Clinic	P4	B (62)
Cefiderocol Cystic Fibrosis	Hartford Hospital	P4	B (62)
Ceftolozane Cystic Fibrosis	Sunshine Coast Hospital and Health Service	P4	B (62)
Cephalexin Autoimmune Disease	Mayo Clinic	P4	B (62)
Cephalexin Diabetes Mellitus	Mayo Clinic	P4	B (62)
Cephalexin Obesity Disorder	Mayo Clinic	P4	B (62)

Showing 2476 to 2500 of 3,229 assets

PreviousPage 100 of 130Next